Cancer
Conditions
Interventions
None listed
Sponsors
Tokushukai Medical Group, General Incorporated Association Tokushukai
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients newly diagnosed with cancer between April 1, 2010 and March 31, 2030 at any Tokushukai Group hospital in Japan that is subject to DPC and has the unified chemotherapy protocol system in place.
Exclusion criteria
Exclusion criteria: Patients who have requested not to participate in this study based on publicly available information. Patients with active multiple cancers (synchronous multiple cancers and heterochronic multiple cancers with a disease-free interval of 5 years or less. However, active duplications do not include carcinoma in situ or intramucosal carcinomas that have been deemed cured by local treatment or lesions diagnosed as intraepithelial or intramucosal by endoscopic findings).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival, time-to-treatment failure | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse effect, prognostic factor | — |
Countries
Japan
Contacts
Public ContactMaki Hayashi
Mirai Iryo Research Center Inc. (N/A)
Outcome results
None listed